Discounted Cash Flow (DCF) Analysis Levered

Esperion Therapeutics, Inc. (ESPR)

$6.7

+0.16 (+2.45%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Revenue (%)
Operating Cash Flow ----------
Operating Cash Flow (%)
Capital Expenditure ----------
Capital Expenditure (%)
Free Cash Flow ----------

Weighted Average Cost Of Capital

Share price $ 6.7
Beta 0.306
Diluted Shares Outstanding 26.46
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 17.81%
Risk-Free Rate
Market Risk Premium
Cost of Equity 5.146
Total Debt 260.20
Total Equity 177.25
Total Capital 437.45
Debt Weighting 59.48
Equity Weighting 40.52
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Operating Cash Flow ----------
Capital Expenditure ----------
Free Cash Flow ----------
WACC
PV LFCF -----
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 12.68
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt 51.30
Equity Value -
Shares Outstanding 26.46
Equity Value Per Share -